BioCentury
ARTICLE | Emerging Company Profile

Breaking bad biofilms

Synspira’s glycopolymers target mechanisms driving decline in pulmonary disorders

August 15, 2018 3:53 PM UTC

Synspira LLC is developing glycopolymers against pulmonary disorders by targeting three mechanisms that exacerbate pulmonary decline: bacteria themselves, the mucus and biofilms that protect them and inflammation that leads to lasting tissue damage.

Synspira in-licensed its technology from therapeutic polysaccharide company Synedgen Inc. in 2017 to develop polycationic glycopolymers in pulmonary indications. Lead product SNSP113 is a derivative of poly-N-acetyl-glucosamine to treat pulmonary exacerbations in cystic fibrosis. Pulmonary exacerbations of CF can be hard to treat because thickened mucus in the lungs keeps antibiotics from reaching bacteria. Adherent biofilms form an extracellular matrix that can play a similar protective role in CF and other respiratory disorders. ...

BCIQ Company Profiles

Anagram Therapeutics Inc.